Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice

Blood

Volumn 120, Issue 26, 2012, Pages 5217-5223

  De Meyer, Simon F ^a,b,c   Savchenko, Alexander S ^a,b   Haas, Michael S ^d   Schatzberg, Daphne ^a,b   Carroll, Michael C ^a,b   Schiviz, Alexandra ^e   Dietrich, Barbara ^e   Rottensteiner, Hanspeter ^e   Scheiflinger, Friedrich ^e   Wagner, Denisa D ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d DecImmune Therapeutics   (United States)

^e BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR; RECOMBINANT HUMAN VON WILLEBRAND FACTOR CLEAVING PROTEINASE; RECOMBINANT PROTEIN; TROPONIN I; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG MEGADOSE; ENZYME ACTIVITY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMATOCRIT; IN VIVO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTHROMBIN TIME; REPERFUSION INJURY; THROMBOCYTE COUNT;

EID: 84871423645     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-439935     Document Type: Article

References (40)

1. Turer AT, Hill JA. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol. 2010;106(3):360-368.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-e209.
3. Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med. 2008;205(9):2065-2074.
4. Chauhan AK, Motto DG, Lamb CB, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006;203(3):767-776.
5. Gandhi C, Khan MM, Lentz SR, Chauhan AK. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood. 2012;119(10):2385-2391.
6. Andersson HM, Siegerink B, Luken BM, et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood. 2012;119(6):1555-1560.
7. Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115(10):2752-2761. (Pubitemid 41434402)
8. Zhao B-Q, Chauhan AK, Canault M, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood. 2009;114(15):3329-3334.
9. De Meyer SF, Vandeputte N, Pareyn I, et al. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol. 2008;28(9):1621-1626.
10. De Maeyer B, De Meyer SF, Feys HB, et al. The distal carboxyterminal domains of murine ADAMTS13 influence proteolysis of plateletdecorated VWF strings in vivo. J Thromb Haemost. 2010;8(10):2305-2312.
11. Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood. 2011;118(12):3212-3221.
12. McCarthy LJ, Danielson CF, Skipworth EM, Peters SL, Miraglia CC, Antony AC. Myocardial infarction/injury is relatively common at presentation of acute thrombotic thrombocytopenic purpura: the Indiana University experience. Ther Apher. 2002;6(1):2-4. (Pubitemid 34218721)
13. Hasper D, Schrage D, Niesporek S, Knollmann F, Barckow D, Oppert M. Extensive coronary thrombosis in thrombotic-thrombocytopenic purpura. Int J Cardiol. 2006;106(3):407-409. (Pubitemid 41766650)
14. Hawkins BM, Abu-Fadel M, Vesely SK, George JN. Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion. 2008;48(2):382-392.
15. Visagie GJ, Louw VJ. Myocardial injury in HIV-associated thrombotic thrombocytopenic purpura (TTP). Transfus Med. 2010;20(4):258-264.
16. Gandhi K, Aronow WS, Desai H, et al. Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience. Clin Cardiol. 2010;33(4):213-216.
17. van Schie MC, van Loon JE, de Maat MP, Leebeek FW. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost. 2011;9(5):899-908.
18. Bongers TN, de Bruijne ELE, Dippel DWJ, et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis. 2009;207(1):250-254.
19. Crawley JTB, Lane DA, Woodward M, Rumley A, Lowe GDO. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost. 2008;6(4):583-588. (Pubitemid 351418945)
20. Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost. 2006;4(11):2490-2493. (Pubitemid 44575447)
21. Matsukawa M, Kaikita K, Soejima K, et al. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol. 2007;100(5):758-763. (Pubitemid 47268262)
22. Horii M, Uemura S, Uemura M, et al. Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation. Heart Vessels. 2008;23(5):301-307.
23. Schettert IT, Pereira AC, Lopes NH, Hueb WA, Krieger JE. Association between ADAMTS13 polymorphisms and risk of cardiovascular events in chronic coronary disease. Thromb Res. 2010;125(1):61-66.
24. Hoshiba Y, Hatakeyama K, Tanabe T, Asada Y, Goto S. Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. J Thromb Haemost. 2006;4(1):114-120.
25. Yamashita A, Sumi T, Goto S, et al. Detection of von Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction. Am J Cardiol. 2006;97(1):26-28. (Pubitemid 41828117)
26. Sakai H, Goto S, Kim JY, et al. Plasma concentration of von Willebrand factor in acute myocardial infarction. Thromb Haemost. 2000;84(2):204-209. (Pubitemid 30601464)
27. Banno F, Chauhan AK, Kokame K, et al. The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood. 2009;113(21):5323-5329.
28. Cresente M, Thomas GM, Demers M, et al. ADAMTS13 exerts a thrombolytic effect in microcirculation. Thromb Haemost. 2012;108(3):527-532.
29. Bodi V, Sanchis J, Nunez J, et al. Uncontrolled immune response in acute myocardial infarction: unraveling the thread. Am Heart J. 2008;156(6):1065-1073.
30. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53(1):31-47. (Pubitemid 34020764)
31. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res. 1999;43(4):860-878. (Pubitemid 29413185)
32. Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation. 1983;67(5):1016-1023. (Pubitemid 13080480)
33. Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation. 1989;80(6):1816-1827. (Pubitemid 20031713)
34. Azab B, Zaher M, Weiserbs KF, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol. 2010;106(4):470-476.
35. Nuñez J, Nunez E, Bodi V, et al. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol. 2008;101(6):747-752.
36. Dragu R, Khoury S, Zuckerman R, et al. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. Atherosclerosis. 2008;196(1):405-412.
37. Fujioka M, Hayakawa K, Mishima K, et al. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood. 2010;115(8):1650-1653.
38. De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke. 2012;43(2):599-606.
39. De Meyer SF, Schwarz T, Deckmyn H, et al. Binding of von Willebrand factor to collagen and glycoprotein Ib{alpha}, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice. Arterioscler Thromb Vasc Biol. 2010;30(10):1949-1951.
40. Kleinschnitz C, De Meyer SF, Schwarz T, et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood. 2009;113(15):3600-3603.